Ευρωπαϊκή Ένωση - Ιταλικά - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - altri agenti antineoplastici - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Ιταλία - Ιταλικά - Ministero della Salute

le vet beheer b.v. - ciclosporina - ciclosporina - 50 milligrammo (i), ciclosporina - 50 mg - selective immunosuppressants

Ευρωπαϊκή Ένωση - Ιταλικά - EMA (European Medicines Agency)

pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.

Ευρωπαϊκή Ένωση - Ιταλικά - EMA (European Medicines Agency)

jazz pharmaceuticals ireland limited - crisantaspase - linfoma di leucemia linfoblastica a cellule precursori - agenti antineoplastici - enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (all) and lymphoblastic lymphoma (lbl) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to e. coli-derived asparaginase.

Ελβετία - Ιταλικά - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - acido tranexamicum - compresse rivestite con film - acido tranexamicum 500 mg, cellulosum microcristallinum, hydroxypropylcellulosum sostituire un basso, talco, magnesio stearas, povidonum k 25, silice colloidalis anhydrica, Überzug: copolymerum methacrylatis butylati formano la base della dieta, e 171, talco, magnesio stearas, macrogolum 8000, vanillinum, per compresso haze. - antifibrinolytikum, haemostatikum - synthetika

Ελβετία - Ιταλικά - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - acido tranexamicum - compresse effervescenti - acido tranexamicum 1000 mg, acido citricum, natrii hydrogenocarbonas, natrii carbonas, natrii citras dihydricus, sono (arancione), per compresso corrisp. sodio 194.27 mg. - antifibrinolytikum, haemostatikum - synthetika

Ιταλία - Ιταλικά - AIFA (Agenzia Italiana del Farmaco)

s.a.l.f. spa laboratorio farmacologico - vitamina k - vitamina k

Ιταλία - Ιταλικά - AIFA (Agenzia Italiana del Farmaco)

teofarma s.r.l. - picotamide - picotamide

Ιταλία - Ιταλικά - AIFA (Agenzia Italiana del Farmaco)

tillomed italia srl - acido tranexamico - acido tranexamico

Ελβετία - Ιταλικά - Swissmedic (Swiss Agency for Therapeutic Products)

servier (suisse) sa - pegaspargasum - poudre versare soluzione iniettabile - pegaspargasum 3750 u. i., sintetico, natrii dihydrogenophosphas anhydricus, dinatrii phosphas, natrii chloridum, per il vetro. - oncaspar è indicato in combinazione con altri agenti antineoplastici per il trattamento della leucemia linfoblastica acuta (all) - biotechnologika